Meabco A/S expands combination trials with more existing anti-cancer drugs

Meabco A/S yesterday announced that very promising pre-clinical results from combination trials with already marketed anti-cancer drugs has made Meabco expanding its preclinical program to include four additional high-profiled anti-cancer drugs.

The company advised that based on earlier study results, which were supported by the drug’s unique mode of action, the combination of efficacy together with a significant reduction of side effects were expected.   “We are talking about a huge market where the combination of Meabco’s most advanced drug candidate and well recognized anti-cancer products already on the market, will be complementary to Meabco’s own anti-cancer drugs.  At the same time the “combination-agents” will have a relatively short time to market” Stig Lofberg, CEO, added.

Meabco, that has its BP-C1 product in Clinical Phase II trials for breast cancer, will start combination products negotiations later this year.

Copenhagen November 7 2007